• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • hRPCs for Retinal Disease
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Observational study in stroke
    • Phase I/IIa clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meeting
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • hRPCs for Retinal Disease
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Observational study in stroke
    • Phase I/IIa clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meeting
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Email alerts

 

Section: Investors

  • The 100 to 1 share consolidation has taken effect
  • General Meeting
  • Email alerts
  • Investor Centre
  • Corporate Governance
  • Share Price Information
  • Major Shareholdings
  • Advisors
  • Analyst Research
  • Webcasts and Presentations
  • Financial Reports
  • Financial Calendar
  • RNS Notifications
  • Documents and Circulars
  • AIM Rule 26
  • Declarations

Subscribe here for our Press Releases:

The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: 

© ReNeuron Group plc 2019 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer